Keros Therapeutics Inc

06/09/2023 | Press release | Distributed by Public on 06/09/2023 04:42

KER-050 Treatment Improved Markers of Erythropoietic Activity and Hematopoiesis Over Six Months Which Resulted in Hematological Responses Across a Broad Lower-Risk MDS Population